Global Market Access
Navigating Global Healthcare Markets with Syenza’s Expertise

Access Beyond Borders
We're inspired by dynamic and diverse global healthcare markets. As a leading value science company, Syenza supports market access activities with global intelligence and local understanding of pricing, reimbursement, and patients. Our philosophy is to drive efficiences through early engagement with payors and decision-makers to increase the probability of success.
Global Market Access Strategy
Syenza enables clients to execute on opportunities by evaluating the market access landscape, analysing current payor reimbursement policies, generating pricing insights, developing an optimized market access strategy, and deploying evidence to support access to innovations.
Outsourced Global Market Access
Syenza provides an Embedded Market Access Team (EMAT) where our interdisciplinary professionals boost capacity with rapid evidence reviews, localized cost breakdowns, stakeholder outreach, training, and market/ competitor scanning.
Value-based Contracting
Syenza scenario builds different approaches to value-based contracting based on demonstrable real-world evidence of the clinical and economic value. Our in-market insights and relationships add depth and nuance to each scenario and improves overall decision-making.
Service Outcomes
Clients receive actionable insights
in Market Access Landscape Reports, Comparative Pricing Reports, and Value-Positioning Workshops.
Clients fill capacity gaps in market access organizations with EMAT to enhance launch and post-launch activities.
Clients apply in-market insights to develop value-based contracts that support access to innovations in different markets.
View Our Recent Case Study
Biopharmaceutical Market Access Analysis in Dubai
August 23, 2022
Objective : A market access landscape analysis is the first step to improving access in the target countries. This involved identifying the unmet need in the disease area, audiences with which to build a shared agenda, and shaping national reimbursem
Read More
View Our Recent Articles
Syenza News
- Ivonescimab Complete Response Letter: FDA Lists Four Reasons November 18, 2026The FDA complete response letter for ivonescimab (BLA 761524) cites China-heavy trial data, a modest PFS gain and the need for a new multiregional trial. Summit must resubmit or take another action within one year.João L. Carapinha
- EU Medical Device Reform Only Partly Fixes Rules for AI-Enabled Medical Devices November 18, 2026Authors writing in npj Digital Medicine say the EU MDR reform eases some burdens for AI-enabled medical devices but leaves adaptive and agentic AI unresolved. #SyenzaNews #MarketAccessJoão L. Carapinha
- FDA Launches Global Reliance Disclosure Program for Approval Packages November 18, 2026The FDA’s Global Reliance Disclosure Program lets companies pass minimally redacted approval packages to regulators outside the US. Lenacapavir is the launch case, and the FDA intends to widen the program in January 2027. #SyenzaNews #MarketAccessJoão L. Carapinha